COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.

Autor: Kochneva ОL; City Clinical Hospital No. 52, Moscow, Russia., Kislova M; Botkin Hospital, Moscow, Russia., Zhelnova EI; City Clinical Hospital No. 52, Moscow, Russia., Petrenko AA; Federal State Budgetary Educational Institution of Further Professional Education 'Russian Medical Academy of Continuous Professional Education' of the Ministry of Healthcare of the Russian Federation.; Department of Radio Engineering and Cybernetics, Moscow Institute of Physics and Technology, Moscow, Russia., Baryakh EA; City Clinical Hospital No. 52, Moscow, Russia.; Federal State Budgetary Educational Institution of Further Professional Education 'Russian Medical Academy of Continuous Professional Education' of the Ministry of Healthcare of the Russian Federation., Yatskov KV; City Clinical Hospital No. 52, Moscow, Russia., Dmitrieva EA; Botkin Hospital, Moscow, Russia.; Federal State Budgetary Educational Institution of Further Professional Education 'Russian Medical Academy of Continuous Professional Education' of the Ministry of Healthcare of the Russian Federation., Misurina EN; City Clinical Hospital No. 52, Moscow, Russia., Nikitin KE; Department of Radio Engineering and Cybernetics, Moscow Institute of Physics and Technology, Moscow, Russia., Vasilieva EJ; Davidovsky City Clinical Hospital, Moscow, Russia., Samsonova IV; City Clinical Hospital No. 52, Moscow, Russia., Ptushkin VV; Botkin Hospital, Moscow, Russia.; Federal State Budgetary Educational Institution of Further Professional Education 'Russian Medical Academy of Continuous Professional Education' of the Ministry of Healthcare of the Russian Federation., Baranova A; School of Systems Biology, George Mason University, Fairfax, VA, USA.; Research Center for Medical Genetics, Moscow, Russia., Nikitin EA; Botkin Hospital, Moscow, Russia.; Federal State Budgetary Educational Institution of Further Professional Education 'Russian Medical Academy of Continuous Professional Education' of the Ministry of Healthcare of the Russian Federation.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1607-1616. Date of Electronic Publication: 2022 Feb 13.
DOI: 10.1080/10428194.2022.2034157
Abstrakt: We describe a retrospective cohort, 156 patients with chronic lymphocytic leukemia (CLL) diagnosed with COVID-19, analyze factors associated with a severe disease course and the effects of various treatment regimens. Anti-SARS-CoV-2 IgG and IgM levels are significantly lower. Patients with CLL are more likely to have a severe course of COVID-19, with IL-6 levels acting as a consistent biomarker of disease severity. Ten patients had recurrent episodes, fatality rate of 20%. Overall survival did not differ between patients receiving ibrutinib monotherapy and anti-CD20 antibodies ± chemotherapy. It seems that the immunodeficiency inherent to CLL influences outcomes to a larger degree than does the treatment. Glucocorticoids are not associated with significant OS improvement whereas anti-cytokine compounds usage seemed to be beneficial in patients with mild pulmonary involvement. Our data attest to the necessity of reorganizing health care for patients with CLL. Early administration of effective antiviral compounds and tailored vaccination protocols are warranted.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje